Drug intelligence / Profile preview

KP182

Development stage: Unknown
Lead developer: Korea Pharma
Modality: Small Molecules

Overview

KP182 is a discovery-stage drug candidate being developed by Korea Pharma for the treatment of depression. It is currently listed in the company's research and development pipeline, though specific details regarding its chemical structure, molecular target, or mechanism of action have not been publicly disclosed. The development of KP182 reflects Korea Pharma's strategic interest in expanding its portfolio within the central nervous system (CNS) therapeutic area.

Other names: KP182KP-182KP 182

Beyond the preview

Go deeper on KP182.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP182.

Explore the full profile